While the testosterone therapy field is under fire from government regulators, Menlo Park, CA-based TesoRx is licensing its oral-testosterone replacement therapy to a subsidiary of South African generics maker Aspen Pharmacare.
Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.
Blaze Bioscience has nabbed a $1.5 million Small Business Innovation Research (SBIR) Phase II award from the National Cancer Institute (NCI) to continue researching its product, called Tumor Paint BLZ-100, which will be studied in people with soft tissue sarcoma. The company was awarded the funding based on the successful completion of a trial in 27 pet dogs with various tumor types.
It's been a productive couple of weeks for Aratana Therapeutics. I had the opportunity to sit down with Aratana CEO Steven St. Peter last week to chat about recent developments, and more generally, the prospects for the animal health industry going forward. Here are some excerpts from our conversation.
The Canadian government is pouring $56 million into 12 projects aimed at translating genomic discoveries into marketable products, including several in the animal health industry. The initiative aims to link up academic institutions with users of genomic research, including drug companies, nonprofit agencies, and government bodies.
Dublin-based Nexvet Biopharma has become the first company to launch a pivotal clinical trial of a monoclonal antibody (mAb) designed to combat pain in dogs with osteoarthritis.
As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer by the end of the year.
Adaptimmune's pioneering approach to cancer immunotherapy has charted some impressive results in a small study. And while the biotech is quick to point out that it's early days yet, the data underscore the potential of a therapy that has convinced GlaxoSmithKline to bet up to $350 million on its future.
Stanford seems to have found a niche in tiny wireless implants. In the latest development, the university announced that it is developing methods of beaming ultrasound to power implanted "smart chips" for the treatment of conditions like Parkinson's disease.